Oklo Inc vs Revvity Inc — how do they compare? Oklo Inc trades at $34.67 (market cap $6.43B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.6× Oklo Inc's market cap, and Revvity Inc pays a 0.18% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 32 Days and Revvity Inc for 12 Days on average.
| OKLO | RVTY | |
|---|---|---|
Market Cap | $6.43B | $16.98B |
Volume | 16,238,368 | 1,456,900 |
Sector | Utilities | Health |
52-Week High | $174.14 | $157.36 |
52-Week Low | $34.57 | $82.26 |
Typical Hold Time | 32 Days | 12 Days |
Enterprise Value | $3.97B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $34.70, down 5.76% in the last 24 hours, with a bearish technical signal from moving averages. The company reported no revenue in 2025 and a net loss of $105.66 million, with a negative net income margin of -12,625.54%. Recent news highlights competition in the nuclear sector and a $1 billion stock sale, while analyst consensus remains bullish with a $78.63 price target.
Outlook: High growth potential in the nuclear energy market, supported by a strong buy rating from analysts. Risks include significant cash burn, lack of revenue, and execution challenges in commercializing reactor technology. The stock's upside depends on successful project deployment and future revenue generation.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →